Cited by 371Blood Coagulation and Thrombosis MechanismsAdipokines, Inflammation, and Metabolic DiseasesProtease and Inhibitor Mechanisms

The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.

Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk

Open access

Juhan-Vague, I., Alessi, M-C., Mavri, A., Morange, P.E.·2003·Journal of Thrombosis and Haemostasis

DOI 10.1046/j.1538-7836.2003.00279.x

Open this paper in CoChat — free account

Abstract

Elevated plasma plasminogen activator inhibitor-1 (PAI-1) level is a core feature of insulin-resistance syndrome (IRS). Atherothrombotic complications in IRS are partly attributed to impaired fibrinolysis caused by increased plasma PAI-1 levels. Although the etiology of IRS is far from being explained, the clustering of inflammation, adipose tissue accumulation and insulin resistance suggests an etiopathological link. Proinflammatory cytokines might regulate PAI-1 expression in IRS; however, more studies are needed to confirm this complex mechanism in humans. Furthermore, modifying PAI-1 expression by PAI-1 inhibitors provides a new challenge and may reveal the true role of PAI-1 in atherosclerotic and insulin resistance processes.

Integrity signals

Registry

Crossref · 10.1046/j.1538-7836.2003.00279.x

Cites

95 of 95 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance
Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., & Spiegelman, B. M. (1996) · Science · doi:10.1126/science.271.5249.665 · Cited by 2,630
C-Reactive Protein in Healthy Subjects: Associations With Obesity, Insulin Resistance, and Endothelial Dysfunction: A Potential Role for Cytokines Originating From Adipose Tissue?
Yudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., & Coppack, S. W. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.972 · Cited by 2,465
Chronic Subclinical Inflammation as Part of the Insulin Resistance Syndrome
Festa, A., D’Agostino, R., Howard, G., Mykkänen, L., Tracy, R. P., & Haffner, S. M. (2000) · Circulation · doi:10.1161/01.cir.102.1.42 · Cited by 2,366
Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-α,in Vivo1
Mohamed‐Ali, V., Goodrick, S., Rawesh, A., Katz, D. R., Miles, J. M., Yudkin, J. S., Klein, S., & Coppack, S. W. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4450 · Cited by 2,032
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial
Hansson, L., Lindholm, L. H., NISKANEN, L. K., Lanke, J., Hedner, T., Niklason, A., LUOMANMÄKI, K., Dahlöf, B., Fairé, U. D., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 1,991
Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ
Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.-W., Karin, M., & Shoelson, S. E. (2001) · Science · doi:10.1126/science.1061620 · Cited by 1,884
Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb
Jiang, J., & Struhl, G. (1998) · Nature · doi:10.1038/35154 · Cited by 1,735
Hyperinsulinemia as an independent risk factor for ischemic heart disease
Després, J.-P., Lamarche, B., Mauriège, P., Cantin, B., Dagenais, G. R., Moorjani, S., & Lupien, P.-J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341504 · Cited by 1,699
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., de Faire, U., Dahlén, G. H., Landou, C., & Wiman, B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)93050-9 · Cited by 1,474
Tumor Necrosis Factor α: A Key Component of the Obesity-Diabetes Link
Hotamışlıgil, G. S., & Spiegelman, B. M. (1994) · Diabetes · doi:10.2337/diab.43.11.1271 · Cited by 1,353
Elevated Levels of Acute-Phase Proteins and Plasminogen Activator Inhibitor-1 Predict the Development of Type 2 Diabetes
Festa, A., D’Agostino, R., Tracy, R. P., & Haffner, S. M. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1131 · Cited by 1,057
Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
Yusuf, S., & Jha, P. (2000) · Cited by 895
Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty
Shimomura, I., Funahasm, T., Takahashi, M., Maeda, K., Kotani, K., Nakamura, T., Yamashita, S., Miura, M., Fukuda, Y., Takemura, K., et al. (1996) · Nature Medicine · doi:10.1038/nm0796-800 · Cited by 889
Interleukin-6 induces cellular insulin resistance in hepatocytes.
Senn, J. J., Klover, P. J., Nowak, I. A., & Mooney, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3391 · Cited by 883
Plasminogen-Activator Inhibitor Type 1 and Coronary Artery Disease
Kohler, H. P., & Grant, P. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006153422406 · Cited by 805
Adipose tissue as a buffer for daily lipid flux
Frayn, K. (2002) · Diabetologia · doi:10.1007/s00125-002-0873-y · Cited by 752
Diabetes and Cardiovascular Disease: The “Common Soil” Hypothesis
Stern, M. P. (1995) · Diabetes · doi:10.2337/diab.44.4.369 · Cited by 739
Prevention of fat-induced insulin resistance by salicylate
Kim, J. K., Kim, Y.-J., Fillmore, J. J., Chen, Y., Moore, I., Lee, J., Yuan, M., Li, Z. W., Karin, M., Perret, P., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11559 · Cited by 737
Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease
Alessi, M., Peiretti, F., Morange, P., Henry, M., Nalbone, G., & Juhan-Vague, I. (1997) · Diabetes · doi:10.2337/diab.46.5.860 · Cited by 614
Self-citation
High Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma Precede a First Acute Myocardial Infarction in Both Men and Women: Evidence for the Fibrinolytic System as an Independent Primary Risk Factor
Thögersen, A. M., Jansson, J.-H., Boman, K., Nilsson, T. K., Weinehall, L., Huhtasaari, F., & Hallmans, G. (1998) · Circulation · doi:10.1161/01.cir.98.21.2241 · Cited by 602
High White Blood Cell Count Is Associated With a Worsening of Insulin Sensitivity and Predicts the Development of Type 2 Diabetes
Vozarova, B., Weyer, C., Lindsay, R. S., Pratley, R. E., Bogardus, C., & Tataranni, P. A. (2002) · Diabetes · doi:10.2337/diabetes.51.2.455 · Cited by 571
Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis
Juhan-Vague, I., Alessi, M., & Vague, P. (1991) · Diabetologia · doi:10.1007/bf00403280 · Cited by 566
Self-citation
Fibrinolytic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients With Angina Pectoris
Juhan-Vague, I., Pyke, S., Alessi, M., Jespersen, J., Haverkate, F., & Thompson, S. G. (1996) · Circulation · doi:10.1161/01.cir.94.9.2057 · Cited by 551
Self-citation
Tumor Necrosis Factor-α Suppresses Adipocyte-Specific Genes and Activates Expression of Preadipocyte Genes in 3T3-L1 Adipocytes
Ruan, H., Hacohen, N., Golub, T. R., Parijs, L. V., & Lodish, H. F. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1319 · Cited by 543
Hyperinsulinemia, Hyperglycemia, and Impaired Hemostasis
Meigs, J. B., Mittleman, M. A., Nathan, D. M., Tofler, G. H., Singer, D. E., Murphy-Sheehy, P., Lipinska, I., D’Agostino, R. B., & Wilson, P. W. F. (2000) · JAMA · doi:10.1001/jama.283.2.221 · Cited by 536
Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover.
Unger, R. H., & Zhou, Y. (2001) · Diabetes · doi:10.2337/diabetes.50.2007.s118 · Cited by 476
Increased Fat Intake, Impaired Fat Oxidation, and Failure of Fat Cell Proliferation Result in Ectopic Fat Storage, Insulin Resistance, and Type 2 Diabetes Mellitus
Ravussin, É., & Smith, S. R. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04292.x · Cited by 466
Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects
Vague, P., Juhan-Vague, I., Aillaud, M. F., Badier, C., Viard, R., Alessi, M., & Collen, D. (1986) · Metabolism · doi:10.1016/0026-0495(86)90209-x · Cited by 443
Self-citation
Inflammatory status and insulin resistance
Grimble, R. F. (2002) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/00075197-200209000-00015 · Cited by 411
Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groups
Nagi, D. K., & Yudkin, J. S. (1993) · Diabetes Care · doi:10.2337/diacare.16.4.621 · Cited by 350
Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity.
Alessi, M. C., Bastelica, D., Morange, P., Berthet, B., Leduc, I., Verdier, M., Geel, O., & Juhan-Vague, I. (2000) · Diabetes · doi:10.2337/diabetes.49.8.1374 · Cited by 344
Self-citation
Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein.
Stiko, A., Wiman, B., Hamsten, A., & Nilsson, J. (1990) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.10.6.1067 · Cited by 295
Increased Plasminogen Activator Inhibitor Activity in Non Insulin Dependent Diabetic Patients – Relationship with Plasma Insulin
Juhan-Vague, I., Roul, C., Alessi, M., Ardissone, J. P., Heim, M., & Vague, P. (1989) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646598 · Cited by 289
Self-citation
Insulin Stimulates the Synthesis of Plasminogen Activator Inhibitor 1 by the Human Hepatocellular Cell Line Hep G2
Alessi, M., Juhan-Vague, I., Kooistra, T., Declerck, P. J., & Collen, D. (1988) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646997 · Cited by 289
Self-citation
Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.
Auwerx, J. H., Bouillon, R., Collen, D., & Geboers, J. (1988) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.8.1.68 · Cited by 276
Targeted Disruption of the Tumor Necrosis Factor-α Gene: Metabolic Consequences in Obese and Nonobese Mice
Ventre, J. R., Doebber, T. W., Wu, M. S., MacNaul, K. L., Stevens, K. A., Pasparakis, M., Kollias, G. A., & Moller, D. E. (1997) · Diabetes · doi:10.2337/diab.46.9.1526 · Cited by 275
Increased Plasminogen Activator Inhibitor Type 1 in Coronary Artery Atherectomy Specimens From Type 2 Diabetic Compared With Nondiabetic Patients
Sobel, B. E., Woodcock‐Mitchell, J., Schneider, D. J., Holt, R. E., Marutsuka, K., & Gold, H. K. (1998) · Circulation · doi:10.1161/01.cir.97.22.2213 · Cited by 270
Insulin Inhibits the Pro-Inflammatory Transcription Factor Early Growth Response Gene-1 (Egr)-1 Expression in Mononuclear Cells (MNC) and Reduces Plasma Tissue Factor (TF) and Plasminogen Activator Inhibitor-1 (PAI-1) Concentrations
Aljada, A., Ghanim, H., Mohanty, P., Kapur, N., & Dandona, P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8462 · Cited by 267
Effects of Ramipril on Plasma Fibrinolytic Balance in Patients With Acute Anterior Myocardial Infarction
Vaughan, D. E., Rouleau, J. L., Ridker, P. M., Arnold, J. M. O., Menapace, F. J., & Pfeffer, M. A. (1997) · Circulation · doi:10.1161/01.cir.96.2.442 · Cited by 264
Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals
Eriksson, P. O., Reynisdottir, S., Lönnqvist, F., Stemme, V., Hamsten, A., & Arner, P. (1998) · Diabetologia · doi:10.1007/s001250050868 · Cited by 228
Tumor necrosis factor α is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1
Samad, F., Uysal, K. T., Wiesbrock, S. M., Pandey, M., Hotamisligil, G. S., & Loskutoff, D. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6902 · Cited by 226
The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance
van Loon, B. J. P., Kluft, C., Radder, J. K., Blankenstein, M. A., & Meinders, A. E. (1993) · Metabolism · doi:10.1016/0026-0495(93)90005-9 · Cited by 225
Stromal Cells Are the Main Plasminogen Activator Inhibitor-1-Producing Cells in Human Fat
Bastelica, D., Morange, P., Berthet, B., Borghi, H., Paulmyer‐Lacroix, O., Grino, M., Juhan-Vague, I., & Alessi, M. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0102.101552 · Cited by 190
Self-citation
Induction of Plasminogen Activator Inhibitor Type-1 (PAI-1) by Proinsulin and Insulin In Vivo
Nordt, T. K., Sawa, H., Fujii, S., & Sobel, B. E. (1995) · Circulation · doi:10.1161/01.cir.91.3.764 · Cited by 185
Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska, Y. T., Yu, J., Olefsky, J. M., & Sobel, B. E. (2000) · Diabetes · doi:10.2337/diabetes.49.4.633 · Cited by 184
Plasma PAI-1 Levels Are More Strongly Related to Liver Steatosis Than to Adipose Tissue Accumulation
Alessi, M., Bastelica, D., Mavri, A., Morange, P., Berthet, B., Grino, M., & Juhan-Vague, I. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000077401.36885.bb · Cited by 178
Self-citation
Disruption of the plasminogen activator inhibitor‐1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice
Schäfer, K., Fujisawa, K., Konstantinides, S., & Loskutoff, D. J. (2001) · The FASEB Journal · doi:10.1096/fj.00-0750fje · Cited by 174
Age-Dependent Spontaneous Coronary Arterial Thrombosis in Transgenic Mice That Express a Stable Form of Human Plasminogen Activator Inhibitor-1
Eren, M., Painter, C., Atkinson, J. B., Declerck, P. J., & Vaughan, D. E. (2002) · Circulation · doi:10.1161/01.cir.0000023186.60090.fb · Cited by 170
Plasminogen Activator Inhibitor Type 1 Is Increased in the Arterial Wall of Type II Diabetic Subjects
Pandolfi, A., Cetrullo, D., Polishuck, R. S., Alberta, M. M., Calafiore, A., Pellegrini, G., Vitacolonna, E., Capani, F., & Consoli, A. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0801.093667 · Cited by 156
Visceral Fat Accumulation and Its Relation to Plasma Hemostatic Factors in Healthy Men
CIGOLINI, M., Targher, G., Andreis, I. A. B., Tonoli, M., Agostino, G., & Sandre, G. D. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.3.368 · Cited by 141
Influence of PAI-1 on Adipose Tissue Growth and Metabolic Parameters in a Murine Model of Diet-Induced Obesity
Morange, P., LIJNEN, H. R., Alessi, M., Kopp, F., Collen, D., & Juhan-Vague, I. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.4.1150 · Cited by 130
Self-citation
Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis.
Nordt, T., Klassen, K. J., Schneider, D. J., & Sobel, B. E. (1993) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.13.12.1822 · Cited by 129
Lack of Plasminogen Activator Inhibitor-1 Promotes Growth and Abnormal Matrix Remodeling of Advanced Atherosclerotic Plaques in Apolipoprotein E–Deficient Mice
Luttun, A., Lupu, F., Storkebaum, E., Hoylaerts, M., Moons, L., Crawley, J. T. B., Bono, F., Poole, A. R., Tipping, P. G., Herbert, J., et al. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0302.104529 · Cited by 123
Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss
Mavri, A., Alessi, M., Georgelin, O., Fina, F., Sentočnik, J. T., Bastelica, D., Stegnar, M., & Juhan-Vague, I. (2001) · Diabetologia · doi:10.1007/s001250100007 · Cited by 121
Self-citation
A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis
Dandona, P., & Aljada, A. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02556-0 · Cited by 121
Metabolic Determinants Are Much More Important Than Genetic Polymorphisms in Determining the PAI-1 Activity and Antigen Plasma Concentrations
Henry, M., Trégouët, D., Alessi, M., Aillaud, M. F., Visvikis‐Siest, S., Siest, G., Tiret, L., & Juhan-Vague, I. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.1.84 · Cited by 121
Self-citation
Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue.
Morange, P., Aubert, J., Peiretti, F., LIJNEN, H. R., Vague, P., Verdier, M., Négrel, R., Juhan-Vague, I., & Alessi, M. (1999) · Diabetes · doi:10.2337/diabetes.48.4.890 · Cited by 115
Self-citation
Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes
Kietzmann, T., Samoylenko, A., Roth, U., & Jungermann, K. A. (2003) · Blood · doi:10.1182/blood-2002-06-1693 · Cited by 103
Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women
Janand-Delenne, B., Chagnaud, C., Raccah, D., Alessi, M., Juhan-Vague, I., & Vague, P. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800585 · Cited by 103
Self-citation
Relationship of Proinsulin and Insulin to Cardiovascular Risk Factors in Nondiabetic Subjects
Haffner, S. M., Mykkänen, L. M., D, M. P. S. M., Valdez, R. A., Heisserman, J. A., & Bowsher, R. R. (1993) · Diabetes · doi:10.2337/diab.42.9.1297 · Cited by 100
Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-α?
CIGOLINI, M., Tonoli, M., Borgato, L., Frigotto, L., Manzato, F., Zeminian, S., Cardinale, C. J., Camin, M., Chiaramonte, E., Sandre, G. D., et al. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(98)00281-0 · Cited by 95
Nutritionally Induced Obesity Is Attenuated in Transgenic Mice Overexpressing Plasminogen Activator Inhibitor-1
LIJNEN, H. R., Maquoi, E., Morange, P., Vörös, G., HOEF, B. V., Kopp, F., Collen, D., Juhan-Vague, I., & Alessi, M. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000044457.60665.dd · Cited by 94
Self-citation
Unsaturated Fatty Acids Increase Plasminogen Activator Inhibitor-1 Expression in Endothelial Cells
Nilsson, L., Banfi, C., Diczfalusy, U., Tremoli, E., Hamsten, A., & Eriksson, P. O. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.11.1679 · Cited by 94
Exclusive Action of Transmembrane TNF in Adipose Tissue Leads to Reduced Adipose Mass and Local But Not Systemic Insulin Resistance
Xu, H., Hirosumi, J., Uysal, K. T., Güler, A. D., & Hotamışlıgil, G. S. (2002) · Endocrinology · doi:10.1210/endo.143.4.8715 · Cited by 93
Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNFα-induced PAI-1 expression
Грубер, Ф., Hufnagl, P., Hofer-Warbinek, R., Schmid, J. A., Breuss, J. M., Huber-Beckmann, R., Lucerna, M., Papac-Miličević, N., Harant, H., Lindley, I. J. D., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2331 · Cited by 93
Liver Steatosis and Its Relation to Plasma Haemostatic Factors in Apparently Healthy Men - Role of the Metabolic Syndrome
CIGOLINI, M., Targher, G., Agostino, G., Tonoli, M., Muggeo, M., & Sandre, G. D. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650524 · Cited by 85
Proinsulin and Insulin Concentrations in Relation to Carotid Wall Thickness
Haffner, S. M., D’Agostino, R., Mykkänen, L. M., Hales, C. N., Savage, P. J., Bergman, R. N., O’Leary, D., Rewers, M., Selby, J. V., Tracy, R. P., et al. (1998) · Stroke · doi:10.1161/01.str.29.8.1498 · Cited by 83
Angiotensin and vascular fibrinolytic balance
Vaughan, D. A. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(01)02273-7 · Cited by 80
Plasminogen Activator Inhibitor Type 1 Increases Neointima Formation in Balloon-Injured Rat Carotid Arteries
DeYoung, M. B., Tom, C., & Dichek, D. A. (2001) · Circulation · doi:10.1161/hc4101.097110 · Cited by 79
Endogenous Vitronectin and Plasminogen Activator Inhibitor-1 Promote Neointima Formation in Murine Carotid Arteries
Peng, L., Bhatia, N., Parker, A. C., Zhu, Y., & Fay, W. P. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000019360.14554.53 · Cited by 74
Plasminogen Activator Inhibitor 1 and Vitronectin Protect Against Stenosis in a Murine Carotid Artery Ligation Model
de Waard, V., Arkenbout, E. K., Carmeliet, P., Lindner, V., & Pannekoek, H. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000042231.04318.e6 · Cited by 66
Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture
Gottschling-Zeller, H., Birgel, M., Röhrig, K., & Hauner, H. (2000) · Metabolism · doi:10.1016/s0026-0495(00)80046-3 · Cited by 65
Plasma PAI-1 Levels in Obese Children – Effect of Weight Loss and Influence of PAI-1 Promoter 4G/5G Genotype
Dalmau, J., Falcó, C., Berbel, O., Castelló, R., España, F., Aznar, J., & Estellés, A. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616100 · Cited by 56
Low-Density Lipoprotein Particle Size Is Inversely Related to Plasminogen Activator Inhibitor-1 Levels
Festa, A., Agostino, R. B. D., Mykkänen, L. M., Tracy, R. P., Howard, B. V., & Haffner, S. M. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.3.605 · Cited by 53
Orexin-A Augments Voltage-Gated Ca2+ Currents and Synergistically Increases Growth Hormone (GH) Secretion with GH-Releasing Hormone in Primary Cultured Ovine Somatotropes
Xu, R., Wang, Q., Yan, M., Hernández, M. I., Gong, C., Boon, W. C., Murata, Y., Ueta, Y., & Chen, C. (2002) · Endocrinology · doi:10.1210/en.2002-220506 · Cited by 53
Syndrome X
Reaven, G. (1999) · Drugs · doi:10.2165/00003495-199958001-00006 · Cited by 49
Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction
Gray, R. P. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(96)06070-4 · Cited by 41
The Fat Mouse: A Powerful Genetic Model to Study Elevated Plasminogen Activator Inhibitor 1 in Obesity/NIDDM
David, J. L., & Samad, F. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657606 · Cited by 41
In Vivo Plasminogen Deficiency Reduces Fat Accumulation
Ellis, J. R., Yuen, L., & Hoover-Plow, J. L. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613126 · Cited by 39
Do PAI-1 and Vitronectin Promote or Inhibit Neointima Formation?
Konstantinides, S., Schäfer, K., & Loskutoff, D. J. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000047462.65341.22 · Cited by 39
The fat mouse: a powerful genetic model to study elevated plasminogen activator inhibitor 1 in obesity/NIDDM.
Samad, F., & Loskutoff, D. J. (1997) · PubMed · Cited by 38
Relationships between fibrinolytic and inflammatory parameters in human adipose tissue: strong contribution of TNFalpha receptors to PAI-1 levels.
Bastelica, D., Mavri, A., Verdier, M., Berthet, B., Juhan-Vague, I., & Alessi, M. (2002) · PubMed · Cited by 38
Self-citation
Plasminogen Activator Inhibitor Type 1 in Ischemic Cardiomyopathy
Cesari, M., & Rossi, G. P. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.6.1378 · Cited by 32
Relationships between Fibrinolytic and Inflammatory Parameters in Human Adipose Tissue: Strong Contribution of TNFα Receptors to PAI-1 Levels
Bastelica, D., Mavri, A., Verdier, M., Berthet, B., Juhan-Vague, I., & Alessi, M. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613241 · Cited by 31
Self-citation
A Forkhead/Winged Helix-related Transcription Factor Mediates Insulin-increased Plasminogen Activator Inhibitor-1 Gene Transcription
Vulin, A. I., & Stanley, F. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112073200 · Cited by 22
Relation between Plasminogen Activator Inhibitor-1 and Hepatic Enzyme Concentrations in Hyperlipidemic Patients
Bruckert, É., Ankri, A., Glral, P., & Turpin, G. (1994) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1648885 · Cited by 19
Hormonal Control of Haemostasis During Hypoglycaemia in Diabetes Mellitus
Grant, P. J., Stickland, M. H., Wiles, P. G., Davies, J. A., Wales, J. K., & Prentice, C. R. M. (1987) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651130 · Cited by 18
10 YEARS AFTER
Richards, D. (2004) · Evidence-Based Dentistry · doi:10.1038/sj.ebd.6400294 · Cited by 15

Research works printed but not linked: 1

Mohamed-Ali, 1997, Human subcutaneous adipose tissue secretes interleukin-6 but not tumour necrosis factor-αin vivo, J Clin Endocrinol Metab, 82, 4196

Sorted by citations

Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Adipose Tissue as an Endocrine Organ
Kershaw, E. E., & Flier, J. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0395 · Cited by 5,522
Inflammation: the link between insulin resistance, obesity and diabetes
Dandona, P. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.10.013 · Cited by 2,170
Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease
Jung, U. J., & Choi, M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15046184 · Cited by 1,971
“vascular cells, such as preadipocytes, fibroblasts, vascular endothelial cells, and a variety of immune cells, in adipose tissue, and its levels in plasma are increased in obesity and insulin resistance [128,129].”
Background
Metabolic Syndrome: Updates on Pathophysiology and Management in 2021
Fahed, G., Aoun, L., Bou Zerdan, M., Allam, S., Bou Zerdan, M., Bouferraa, Y., & Assi, H. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020786 · Cited by 1,441
“Together, RAS, LOX-1, and ROS form a positive feedback loop and induce a vicious cycle of endothelial dysfunction, inflammation, and fibroblast proliferation, leading to the progression of dyslipidemia, T2DM, hypertension, vasculopathies, and CVDs [63–65].”
BackgroundInfluential

See all 371

Authors: Juhan-Vague, I., Alessi, M.-C., Mavri, A., & Morange, P. E.
Affiliations: Inserm (FR)
Corresponding author: Juhan-Vague, I.
ORCID: Alessi, M-C.
Mavri, A.
Morange, P.E.
Venue: Journal of Thrombosis and Haemostasis
Publisher: Elsevier BV
Published: 2003-07
Volume: 1
Issue: 7
Pages: 1575-1579
ISSN: 1538-7836 (ISSN-L)
DOI: 10.1046/j.1538-7836.2003.00279.x
OpenAlex: W2042742088
Cited by: 371
References: 95
Citations by year: 2026: 9 · 2025: 13 · 2024: 13 · 2023: 8 · 2022: 14 · 2021: 6 · 2020: 11 · 2019: 14 · 2018: 10 · 2017: 17 · 2016: 9 · 2015: 19 · 2014: 14 · 2013: 11 · 2012: 13
FWCI: 4.40
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 7104 d)
Locations: Journal of Thrombosis and Haemostasis (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
Keywords: plasminogen activator inhibitor-1, metabolic syndrome, inflammation, obesity, adipose tissue, inflammatory cytokines, impaired fibrinolysis, atherothrombosis, vascular risk, PAI-1 inhibitors, atherosclerosis
MeSH terms: Animals, Heart Diseases, Humans, Insulin Resistance, Obesity, Risk, Plasminogen Activator Inhibitor 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks